A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Clinical trial NCT00051116 · COMPLETED

Trial details

NCT number: NCT00051116
Sponsor: Celgene Corporation
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2002-05-01
Primary completion: 2006-10-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.